Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan DDI Study with Midazolam in Healthy Volunteers
NCT04545944Phase 1Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vonoprazan in gastroesophageal reflux disease (GERD), sponsored by Phathom Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration at Day 9, Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity at Day 9 and 1 more. Started Sep 2020; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04545944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545944.